Quarterly Results of Operations (Unaudited)

12 Months Ended

Jun. 30, 2018

Quarterly Financial Information Disclosure [Abstract]

Quarterly Results of Operations

Quarterly Results of Operations (Unaudited)

The following table present summarized unaudited quarterly financial data:

	Three Months Ended
(In thousands, except for per share amounts)	June 30, 2018			March 31, 2018			December 31, 2017			September 30, 2017
Consolidated Statements of Comprehensive Loss Data:
Revenues	$	387		$	482		$	597		$	690
Net loss attributable to Immunomedics, Inc. stockholders	$	(117,032	)	$	(35,546	)	$	(2,514	)	$	(118,745	)
Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted)	$	(0.68	)	$	(0.21	)	$	(0.02	)	$	(0.97	)
Weighted average shares used to calculate loss per common share – (basic and diluted)	171,124			166,054			154,487			122,550

	Three Months Ended
(In thousands, except for per share amounts)	June 30, 2017			March 31, 2017			December 31, 2016			September 30, 2016
Consolidated Statements of Comprehensive Loss Data:
Revenues	$	642		$	1,323		$	384		$	742
Net loss attributable to Immunomedics, Inc. stockholders	$	(53,255	)	$	(59,306	)	$	(24,447	)	$	(16,198	)
Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted)	$	(0.48	)	$	(0.56	)	$	(0.25	)	$	(0.18	)
Weighted average shares used to calculate loss per common share – (basic and diluted)	109,891			107,840			104,657			95,884